ConvaTec Group (LON:CTEC) Earns “Buy” Rating from Deutsche Bank Aktiengesellschaft

ConvaTec Group (LON:CTEC)‘s stock had its “buy” rating reaffirmed by equities researchers at Deutsche Bank Aktiengesellschaft in a note issued to investors on Wednesday, Marketbeat.com reports. They currently have a GBX 315 target price on the stock. Deutsche Bank Aktiengesellschaft’s target price indicates a potential upside of 40.96% from the stock’s current price.

Other research analysts also recently issued reports about the company. Berenberg Bank lifted their price target on ConvaTec Group from GBX 330 to GBX 340 and gave the stock a “buy” rating in a research report on Thursday, January 22nd. Citigroup reaffirmed an “outperform” rating and issued a GBX 315 price target on shares of ConvaTec Group in a research report on Thursday, March 5th. Finally, Stifel Nicolaus reaffirmed a “buy” rating and issued a GBX 315 price target on shares of ConvaTec Group in a research report on Wednesday, March 11th. Eight investment analysts have rated the stock with a Buy rating, Based on data from MarketBeat, ConvaTec Group currently has a consensus rating of “Buy” and an average price target of GBX 319.

ConvaTec Group Stock Down 0.6%

CTEC opened at GBX 223.47 on Wednesday. The business has a 50 day moving average price of GBX 230.44 and a 200 day moving average price of GBX 234.89. ConvaTec Group has a twelve month low of GBX 209.40 and a twelve month high of GBX 311.20. The company has a debt-to-equity ratio of 106.19, a quick ratio of 0.96 and a current ratio of 1.53. The firm has a market cap of £4.37 billion, a P/E ratio of 25.98, a price-to-earnings-growth ratio of 0.93 and a beta of 0.84.

Insiders Place Their Bets

In related news, insider Jonny Mason sold 291,149 shares of the stock in a transaction dated Monday, March 16th. The shares were sold at an average price of GBX 234, for a total value of £681,288.66. 0.95% of the stock is currently owned by insiders.

ConvaTec Group Company Profile

ConvaTec Group PLC engages in the development, manufacturing, and sale of medical products, services, and technologies in Europe, North America, and internationally. The company offers advanced wound dressings and skin care products for the management of acute and chronic wounds resulting from various conditions, such as diabetes, and acute conditions resulting from traumatic injury and burns. It also provides ostomy care solutions, including devices, accessories, and services for people with a stoma resulting from colorectal cancer, inflammatory bowel disease, and bladder cancer.